GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » EV-to-Revenue

Extrawell Pharmaceutical Holdings (HKSE:00858) EV-to-Revenue : 1.61 (As of May. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Extrawell Pharmaceutical Holdings's enterprise value is HK$110.68 Mil. Extrawell Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was HK$68.62 Mil. Therefore, Extrawell Pharmaceutical Holdings's EV-to-Revenue for today is 1.61.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's EV-to-Revenue or its related term are showing as below:

HKSE:00858' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.21   Med: 4.04   Max: 11.15
Current: 1.61

During the past 13 years, the highest EV-to-Revenue of Extrawell Pharmaceutical Holdings was 11.15. The lowest was 1.21. And the median was 4.04.

HKSE:00858's EV-to-Revenue is ranked better than
65.04% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs HKSE:00858: 1.61

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Extrawell Pharmaceutical Holdings's stock price is HK$0.038. Extrawell Pharmaceutical Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03. Therefore, Extrawell Pharmaceutical Holdings's PS Ratio for today is 1.52.


Extrawell Pharmaceutical Holdings EV-to-Revenue Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings EV-to-Revenue Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.76 1.92 4.02 2.42 2.19

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.42 - 2.19 -

Competitive Comparison of Extrawell Pharmaceutical Holdings's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's EV-to-Revenue falls into.



Extrawell Pharmaceutical Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Extrawell Pharmaceutical Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=110.679/68.623
=1.61

Extrawell Pharmaceutical Holdings's current Enterprise Value is HK$110.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Extrawell Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was HK$68.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Extrawell Pharmaceutical Holdings  (HKSE:00858) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Extrawell Pharmaceutical Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.038/0.025
=1.52

Extrawell Pharmaceutical Holdings's share price for today is HK$0.038.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Extrawell Pharmaceutical Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines